Table 2.
Demographic and clinical characteristics of early and advanced-stages NSCLC patients in TCGA database cohort
| N = 914 | Methylated | Unmethylated | p-value | |
|---|---|---|---|---|
| TCGA cohort: early-stage | ||||
| Sex | ||||
| Female | 372 | 295 (79%) | 77 (21%) | < 0.01 |
| Male | 542 | 307 (57%) | 235 (43%) | |
| Smoking status | ||||
| Current smoker | 809 | 510 (63%) | 299 (37%) | < 0.01 |
| Never smoker | 83 | 77 (93%) | 6 (7%) | |
| n.a. | 22 | |||
| Tumor histologic type | ||||
| Adenocarcinoma | 446 | 423 (95%) | 23 (5%) | < 0.01 |
| Squamous | 468 | 179 (38%) | 289 (62%) | |
| Stage | ||||
| IA | 221 | 156 (71%) | 65 (29%) | < 0.045 |
| IB | 278 | 187 (67%) | 91 (33%) | |
| IIA | 113 | 63 (56%) | 50 (44%) | |
| IIB | 160 | 98 (61%) | 62 (39%) | |
| IIIA | 130 | 90 (69%) | 40 (31%) | |
| n.a. | 12 | |||
| N = 55 | Methylated | Unmethylated | p-value | |
|---|---|---|---|---|
| TCGA cohort: advanced-stage | ||||
| Sex | ||||
| Female | 17 | 15 (88%) | 2 (12%) | 0.12 |
| Male | 38 | 26 (68%) | 12 (32%) | |
| Smoking status | ||||
| Current smoker | 45 | 32 (70%) | 13 (30%) | 0.10 |
| Never smoker | 7 | 0 (0%) | 7 (100%) | |
| n.a. | 3 | |||
| Tumor histologic type | ||||
| Adenocarcinoma | 29 | 27 (93%) | 2 (7%) | 0.01 |
| Squamous | 26 | 14 (54%) | 12 (46%) | |
| Stage | ||||
| IIIB | 26 | 17 (65%) | 9 (35%) | 0.14 |
| IV | 29 | 24 (83%) | 5 (17%) | |
MiR-7 methylation related to gender, smoking status, tumor histologic type, stage and RECIST
n.a. result not available in TCGA cohort